Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

British Journal of Cancer

Volumn 81, Issue 7, 1999, Pages 1127-1133

  Chinje, E C ^a   Patterson, A V ^a   Saunders, M P ^a   Lockyer, S D ^a   Harris, A L ^b   Stratford, I J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bioreductive drug; Cytotoxicity; DNA damage; Hypoxia; Lung cancer; NADPH:cytochrome P450 reductase; Tirapazamine

Indexed keywords

PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL METABOLISM; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METABOLIC ACTIVATION; PRIORITY JOURNAL;

EID: 0032759462     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690819     Document Type: Article

References (52)

1. Adams GE and Stratford IJ (1986) Hypoxia-mediated nitro-heterocyclic drugs in the radio and chemotherapy of cancer: an overview. Biochem Pharmacol 35: 71-78
2. Adams GE and Stratford IJ (1994) Bioreductive drugs for cancer therapy: the search for tumour specificity. Int J Radiat Oncol Biol Phys 29: 231-238
3. Arteel GE, Thurman RG and Raleigh JA (1998) Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 253: 743-750
4. Barham HM, Patterson AV, Chinje EC, Harris AL and Stratford IJ (1995) Sensitivity to tirapazamine (SR 4233) is determined by P450 reductase in human breast but not lung cancer cell lines. Br J Cancer 71: 20
5. Biaglow JE, Jacobson B, Greenstock CL and Raleigh J (1977) Mol Pharmacol 13: 262.
6. Biedermann KA, Wang J, Graham RP and Brown JM (1991) SR 4233 cytotoxicity and metabolism in DNA repair-competent and DNA repair-deficient cell cultures. Br J Cancer 63: 358-362
7. Brown JM (1993) SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163-1170
8. Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745-7749
9. Brown JM and Lemmon MJ (1991) Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20: 457-461
10. Cabill A and White INH (1990) Reductive metabolism of 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis 11: 1407-1411
11. Carmichael J, De Graff WG, Gazdar AF, Minna JD and Mitchell JB (1987) Evaluation of a tetrazolium based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-941
12. Chinje EC, Saunders MP, Patterson AV, Harris AL and Stratford IJ (1998) Using gene therapy to determine the mechanism of hypoxic activation of tirapazamine. B J Cancer 78: SL p. P27.
13. Costa AK, Baker MA, Brown JM and Trudell JR (1989) In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res 49: 925-929
14. Dorie MJ and Blown JM (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633-4636
15. Durand RE (1994) The influence of microenvironmental factors during cancer therapy. In vivo 8: 691-702
16. Elwell JH, Siim BG, Evans JW and Brown JM (1997) Adaptation of human tumor cells to tirapazamine under aerobic conditions; Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol 54: 249-257
17. Evans JW, Yudoh K, Delahoussaye YM and Brown JM (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58: 2098-2101
18. Fitzsimmons SA, Lewis AD, Riley RJ and Workman P (1994) Reduction of 3-amino-1,2,4-benzotriazine 1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15: 1503-1510
19. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH and Bbroder GJ (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to the outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831-838
20. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45-50
21. Houlbrook S, Kirk J, Stuart NSA, Stratford IJ, Harris AL, Pettit GR and Carmichael J (1994) Human tumour cell lines: a valuable model for evaluating new drugs and the mechanism underlying cytotoxic drug resistance. Oncol (Life Sci Adv) 13: 69-76
22. Jones DP (1981) Hypoxia and drug metabolism. Biochem Pharmacol 30: 1019-1023
23. Kim IH and Brown JM (1994) Reoxygenation and rehypoxiation in SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 29: 493-497
24. Koch CJ (1993) Unusual oxygen concentration dependence of toxicity of SR 4233, a hypoxic cell toxin. Cancer Res 53: 3992-3997
25. Lloyd RV, Duling DR, Rumyantseva GV, Mason RP and Bridson PK (1991) Microsomal reduction of 3-amino-1,24-benzotriazine 1,4 dioxide to a free radical. Mol Pharmacol 40: 440-445
26. Mossman T (1983) Rapid colorimetric assay for the cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-61
27. Nordsmark M, Overgaard M and Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiather Oncol 41: 31-40
28. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C and Vaupel P (1993) Oxygen tension distributions are sufficient to explain the local response of human breast tumours treated with radiation alone. Int J Radiat Oncol Biol Phys 26: 631-636
29. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72: 1144-1150
30. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL and Stratford IJ (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76: 1338-1347
31. Patterson AV, Saunders MP, Chinje EC, Patterson LH and Stratford IJ (1998) Enzymology of tirapazamine metabolism: a review. Anti Cancer Drug Design 13: 541-573
32. Plumb JA, Milroy R and Kaye SB (1989) Effects of the pH dependence of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49: 4435-4440
33. Riley RJ and Workman P (1992) Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem Pharmacol 43: 467-
34. Riley RJ, Hemingway SA, Graham MA and Workman P (1993) Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem Pharmacol 45: 1065-
35. Robertson N, Haigh A, Adams GE and Stratford IJ (1994) Factors affecting sensitivity to EO9 in rodent and human tumour cells in vivo: DT-diaphorase and hypoxia. Eur J Cancer 30A: 1013-1019
36. Saunders MP, Chinje EC, Patterson AV, Harris AL and Strafford IJ (1999) NADPH:cytochrome c (P450) reductase activates tirapazamine to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. (in press).
37. Seng F and Ley K (1972) Simple synthesis of 3-amino-1,24-benzotriazine-1,4-dioxide. Angew Chem Int XI: 1009-1010
38. Siim BG, Van Ziji PL and Brown JM (1996) Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 73: 952-
39. Silva JM and O'Brien PJ (1993) Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. Br J Cancer 68: 484-491
40. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Groeke NM, Olaon BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85
41. Stratford IJ and Stephens MA (1989) The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 16: 973-976
42. Teicher BA (1994) Hypoxia and drug resistance. Cancer and Metastasis Rev 13: 139-168
43. Varnes ME, Tuttle SW and Biaglow JE (1984) Nitroheterocycle metabolism in mammalian cells. Stimulation of the hexose monophosphate shunt. Biochem Pharmacol 33: 1671-1677
44. Von Pawal J and Von Roemeling R (1998) Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT I trial. Proc Am Soc Clin Oncol 17: 454a
45. Walton MI and Workman P (1990) Enzymology of the reductive activation of SR 4233: a novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol 39: 1735-1742
46. Walton MI, Wolf CR and Workman P (1989) Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 16: 983-986
47. Walton MI, Wolf CR and Workman P (1992) The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hyposic cytotoxin 3-amino-1,2,4-benzotriazine-1, 4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 44: 251-259
48. Wang J, Biedermann KA and Brown JM (1992) Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 52: 4473-4477
49. Wang J, Biedermann KA, Wolf CR and Brown JM (1993) Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br J Cancer 67: 321-325
50. Williams CH Jr and Kamin H (1962) Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem 237: 587-595
51. Wouters BG and Brown JM (1997) Cells at intermediate oxygen levels can be more important than the 'hypoxic fraction' in determining tumor response to fractionated radiotherapy. Radiat Res 147: 541-550
52. Zeman EM, Brown JM, Lemmon MJ, Hirst VK and Lee WW (1986) SR4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239-1242